{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335368","form_type":"8-K","ticker":"BIOA","cik":"0001709941","company_name":"BioAge Labs, Inc.","filed_at":"2026-08-05T20:55:14+00:00","discovered_at":"2026-08-05T20:56:10.251966+00:00","generated_at":"2026-08-05T20:56:15.683115+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioAge Labs Q2 net loss $26.1M; dosed first participant in Phase 2 BGE-102 trial","bullets":["Net loss $26.1M ($0.58/share) vs $21.6M ($0.60/share) in Q2 2025; R&D spend up $4.6M to $24.4M.","First participant dosed in QUELL-CV Phase 2 trial of BGE-102 (NLRP3 inhibitor); topline data expected H2 2026.","Cash, cash equivalents, and marketable securities $381.3M as of June 30, 2026; sufficient through 2029.","QUELL-DME Phase 1b/2a trial in diabetic macular edema planned to start mid-2026, data mid-2027.","Collaboration revenue flat at $2.4M; APJ agonist IND planned by year-end 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335368","json":"https://secwatch.observer/filing/0001193125-26-335368.json","markdown":"https://secwatch.observer/filing/0001193125-26-335368.md","text":"https://secwatch.observer/filing/0001193125-26-335368.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/0001193125-26-335368-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:56:15.683115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}